文献速递关节外科

慢性乙型肝炎感染抗病毒治疗改善全髋关节置换术后结局:一项多中心回顾性研究

Antiviral Therapy for Chronic Hepatitis B Infection Improves Outcomes After Total Hip Arthroplasty: A Multicenter Retrospective Study.
PubMed 文献 · J Arthroplasty · 2022-08-11

这项多中心回顾性研究纳入918例慢性HBV感染并行全髋关节置换术的患者,比较术前接受与未接受抗病毒治疗者的术后结局。未治疗组手术时间更长、失血量更多,手术并发症、住院时间、再入院、再手术和翻修率均更高;多因素回归显示抗病毒治疗可降低显著肝纤维化患者的各类并发症、再手术和翻修风险。

要点

  • 慢性HBV感染患者中83.0%术前未接受抗病毒治疗,54.1%未治疗者此前未确诊。
  • 未治疗组手术并发症25.4% vs 治疗组16.7%,再入院12.4% vs 5.8%,再手术16.7% vs 9.6%,翻修11.1% vs 4.5%。
  • 多因素回归显示抗病毒治疗可降低显著肝纤维化患者的各类并发症、再手术和翻修风险(均P < .05)。

核心结论

  • 全髋关节置换术前对HBV感染进行抗病毒治疗可降低术后并发症风险,无论是否存在肝纤维化。
  • 作者强调外科医生应将HBV筛查和治疗纳入术前内科优化。

研究设计与样本

  • 多中心回顾性数据库查询,识别2012年至2017年间接受全髋关节置换术的HBV感染患者。
  • 按术前是否接受抗病毒治疗分为治疗组和未治疗组,采用倾向性评分按1:3匹配。
  • 共识别918例慢性HBV感染患者,比较两组手术时间、失血量、各类并发症、手术并发症、住院时间、90天再入院、非计划再手术和假体翻修。

主要发现

  • 未治疗组平均手术时间82分钟 vs 治疗组76分钟(P = .007),未治疗组更长。
  • 未治疗组平均失血量515 mL vs 治疗组465 mL(P = .03),未治疗组更高。
  • 未治疗组手术并发症25.4% vs 治疗组16.7%(P = .01),未治疗组更高。
  • 未治疗组住院时间6.2天 vs 治疗组5.4天(P = .0005),未治疗组更长。
  • 未治疗组再入院12.4% vs 治疗组5.8%(P = .02),再手术16.7% vs 9.6%(P = .03),翻修11.1% vs 4.5%(P = .02),未治疗组均更高。

关键数值与推荐

  • 83.0%的慢性HBV感染患者未接受术前抗病毒治疗。
  • 54.1%的未治疗患者此前未确诊HBV感染。
  • 多因素回归分析显示,在显著肝纤维化患者中,抗病毒治疗显著降低各类并发症、再手术和翻修风险(均P < .05)。

临床怎么用

  • 作者认为,全髋关节置换术前对HBV感染进行抗病毒治疗可降低术后并发症风险,无论是否存在肝纤维化。
  • 作者建议外科医生应将HBV筛查和治疗纳入术前内科优化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies have shown that chronic hepatitis B virus (HBV) infection may place patients at increased risk of postoperative adverse events. However, there is limited information on the effects of antiviral treatment (AVT) on postoperative outcomes following total hip arthroplasties (THAs). METHODS: A multicenter retrospective database query was used to identify patients infected with HBV undergoing THAs between 2012 and 2017. All eligible patients were divided into 2 cohorts on the basis of AVT before surgery: the treated group and the untreated group. The treated cohort was matched at a ratio of 1:3 to the untreated cohort by propensity score matching. Operating times, blood losses, all-type complications, surgical complications, lengths of stay, 90-day readmissions, unplanned reoperations, and implant revisions were compared between the 2 cohorts. After these patients were further stratified by liver fibrosis status, multivariate logistic analyses were performed by controlling for differences in demographics and comorbidities. In total, 918 patients chronically infected with HBV were identified. Over four-fifths of these patients (83.0%) did not receive preoperative AVT. Of interest, more than half of the untreated patients (54.1%) were previously undiagnosed. RESULTS: The untreated group had significantly longer mean operating time (82 versus 76 minutes, P = .007) and higher mean blood loss (515 versus 465 mL, P = .03) than the treated group. Moreover, they were more prone to experiencing surgical complications (25.4% versus 16.7%, P = .01), longer lengths of stay (6.2 versus 5.4 days, P = .0005), readmissions (12.4% versus 5.8%, P = .02), reoperations (16.7% versus 9.6%, P = .03), and revisions (11.1% versus 4.5%, P = .02). Multivariate regression analyses found that AVT significantly decreased all-type complications, reoperations, and revisions in patients with significant fibrosis (all P < .05). CONCLUSION: The AVT of HBV infection prior to THAs could reduce the risk of developing postoperative complications, regardless of the presence of liver fibrosis. This finding emphasizes that surgeons should recommend HBV screening and treatment integrated into preoperative medical optimization.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Cheng T, Li G, Ning H, et al. Antiviral Therapy for Chronic Hepatitis B Infection Improves Outcomes After Total Hip Arthroplasty: A Multicenter Retrospective Study. J Arthroplasty. 2022. PMID: 35963280. doi:10.1016/j.arth.2022.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。